Facial Angiofibroma Associated with Tuberous Sclerosis Complex Now Has an FDA Approved Topical Therapy
Nobelpharma has just announced the FDA approval of sirolimus .2% gel (called Hyftor). It is now the first approved, topical therapy for facial angiofibroma associated with the rare condition tuberous…
Continue Reading
Facial Angiofibroma Associated with Tuberous Sclerosis Complex Now Has an FDA Approved Topical Therapy
